Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical
company focused on discovering and developing drugs to treat cancer by
the targeted killing of cancer stem cells, announced that members of the
management team will be presenting at the 23rd Annual
Oppenheimer Healthcare Conference being held December 12-13, 2012 at the
Waldorf-Astoria in New York, NY. The presentation details are as follows:
A panel discussion titled “Toward Personalized Medicine” on Thursday,
December 13, 2012 at 8:35 am ET in the Jade room.
Corporate presentation on Thursday, December 13, 2012 at 1:35 pm ET in
the Basildon room.
Webcasts of the presentations can be accessed by visiting the investors
section of the Company’s website at www.verastem.com.
A replay of the webcasts will be archived on the Verastem website for
two weeks following the presentation date.
About Verastem, Inc. Verastem, Inc. (NASDAQ: VSTM) is a
clinical-stage biopharmaceutical company focused on discovering and
developing drugs to treat cancer by the targeted killing of cancer stem
cells. Cancer stem cells are an underlying cause of tumor recurrence and
metastasis. Verastem is developing small molecule inhibitors of
signaling pathways that are critical to cancer stem cell survival and
proliferation: FAK, PI3K/mTOR and Wnt. For more information, please
Forward-looking statements: Any statements in this press
release about future expectations, plans and prospects for the Company
constitute forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements. The
Company anticipates that subsequent events and developments will cause
the Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so.